Malin, an Irish-based global life sciences company, has invested €73 million in British biotech company Immunocore. Immunocore, one of the world's leading biotechnology companies, develops novel T cell receptor (TCR) based therapies with the potential to treat a variety of cancers, viral infections and autoimmune diseases. Malin joins Woodford Investment Management, Eli Lilly, RTW Funds as well as a number of existing investors in Immunocore in a financing round of €290 million, Europe's largest ever Series A life sciences financing. Malin CEO Adrian Howd and director Kelly Martin will join the board of Immunocore. “For Malin and its shareholders, this represents a second significant investment in a UK-based biotech company,” said Howd. “Given its unique and innovative science, a balanced pipeline with possible applications across a number of therapeutic areas, and first-class executive team and board leadership, we believe Immunocore has the potential to create a highly unique premier biotech company and establish itself as a substantial enterprise and thought leader within the industry," he added. The proceeds of the funding will allow Immunocore to further accelerate its pipeline of ImmTACs (Immune mobilising mTCR Against Cancer). ImmTACs are a new class of bispecific biologics which have the potential to treat a broad range of solid tumours either as monotherapies or in combination with other therapies. Immunocore intends to focus on progressing its lead proprietary programme, IMCgp100, which produced positive Phase I/IIa trial data announced in April 2015 in patients with advanced metastatic cutaneous and ocular melanoma.